Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RAPP Stock Forecast 2025-2026
$11.03
Current Price
$402.57M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to RAPP Price Targets
+280.8%
To High Target of $42.00
+217.3%
To Median Target of $35.00
+153.9%
To Low Target of $28.00
RAPP Price Momentum
-1.4%
1 Week Change
+7.9%
1 Month Change
-50.3%
1 Year Change
-37.8%
Year-to-Date Change
-62.9%
From 52W High of $29.74
+71.5%
From 52W Low of $6.43
📊 TOP ANALYST CALLS
Did RAPP Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rapport is one of their latest high-conviction picks.
Latest RAPP Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, RAPP has a bullish consensus with a median price target of $35.00 (ranging from $28.00 to $42.00). Currently trading at $11.03, the median forecast implies a 217.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at Jones Trading, projecting a 280.8% upside. Conversely, the most conservative target is provided by Jason Butler at JMP Securities, suggesting a 153.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPP Analyst Ratings
5
Buy
0
Hold
0
Sell
RAPP Price Target Range
Low
$28.00
Average
$35.00
High
$42.00
Current: $11.03
Latest RAPP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2025 | JMP Securities | Jason Butler | Market Outperform | Initiates | $28.00 |
| Oct 18, 2024 | Jones Trading | Justin Walsh | Buy | Initiates | $42.00 |
| Jul 2, 2024 | Jefferies | Andrew Tsai | Buy | Initiates | $35.00 |
| Jul 2, 2024 | Stifel | Paul Matteis | Buy | Initiates | $35.00 |
| Jul 2, 2024 | TD Cowen | Joseph Thome | Buy | Initiates | $0.00 |
Rapport Therapeutics Inc. (RAPP) Competitors
The following stocks are similar to Rapport based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
RAPP
Rapport Therapeutics
mkt cap
408.59M
Rapport Therapeutics Inc. (RAPP) Financial Data
Rapport Therapeutics Inc. has a market capitalization of $402.57M with a P/E ratio of -2.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -33.1%.
Valuation Metrics
Market Cap
$402.57M
Enterprise Value
$125.03M
P/E Ratio
-2.9x
PEG Ratio
-3.4x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+70.9%
Current Ratio
31.0x
Debt/Equity
2.7x
ROE
-33.1%
ROA
-22.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rapport Therapeutics Inc. (RAPP) Business Model
About Rapport Therapeutics Inc.
What They Do
Develops neurological medicines for unmet needs.
Business Model
Rapport Therapeutics Inc. operates within the biotechnology sector, focusing on creating therapies for neurological disorders. The company generates revenue by discovering and developing drug candidates through its integrated platform that combines neuroscience, medicinal chemistry, and genetics, targeting specific neurological issues.
Additional Information
The company aims to improve treatment options for conditions like epilepsy, neuropathic pain, and psychiatric disorders. As it tackles the challenges presented by traditional treatment methods, Rapport Therapeutics positions itself as a key innovator in the biotech industry, contributing to advancements in healthcare and enhancing patient quality of life.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
69
CEO
Mr. Abraham N. Ceesay M.B.A.
Country
United States
IPO Year
N/A
Website
www.rapportrx.comRapport Therapeutics Inc. (RAPP) Latest News & Analysis
Latest News
Quick Summary
The biopharmaceuticals industry offers growth opportunities for investors, with stocks often seeing significant gains from positive trial results or government drug approvals.
Why It Matters
Biopharmaceuticals offer high growth potential linked to trial successes and regulatory approvals, creating volatility that can lead to substantial investment gains or losses.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
The Phase 2a trial of RAP-219 for refractory focal epilepsy is fully enrolled and expected to report topline results in September 2025.
Why It Matters
The successful enrollment and upcoming results of the RAP-219 trial could impact the stock value and market perception of the company, influencing investment decisions in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics, Inc. (Nasdaq: RAPP) will participate in two upcoming investor conferences, focusing on small molecule precision medicines for neurological and psychiatric disorders.
Why It Matters
Rapport Therapeutics' participation in investor conferences signals potential growth and investor interest, which may enhance visibility and attract capital for its innovative drug development efforts.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics, Inc. (Nasdaq: RAPP) will hold its first Investor and Analyst Day on June 2, 2025, in New York City, with a live webcast available.
Why It Matters
Rapport Therapeutics' Investor Day signals potential insights into its pipeline and strategy, which could influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Rapport Therapeutics expects topline results for its RAP-219 Phase 2a trials in refractory focal epilepsy and bipolar mania in 2025 and 2027, respectively. The company has $285.4M in cash, funding operations through 2026.
Why It Matters
RAP-219's ongoing trials and strong cash position indicate potential breakthroughs in epilepsy and bipolar mania, impacting future stock performance and investor interest in Rapport Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
CROSSJECT has released its 2024 annual financial report, now available to the public and submitted to the French Financial Markets Authority. The report can be accessed on the company's website.
Why It Matters
The release of the annual financial report provides insights into CROSSJECT's performance and developments, particularly regarding ZEPIZURE®, impacting investor confidence and stock valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RAPP Stock
What is Rapport Therapeutics Inc.'s (RAPP) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Rapport Therapeutics Inc. (RAPP) has a median price target of $35.00. The highest price target is $42.00 and the lowest is $28.00.
Is RAPP stock a good investment in 2025?
According to current analyst ratings, RAPP has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.03. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPP stock?
Wall Street analysts predict RAPP stock could reach $35.00 in the next 12 months. This represents a 217.3% increase from the current price of $11.03. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapport Therapeutics Inc.'s business model?
Rapport Therapeutics Inc. operates within the biotechnology sector, focusing on creating therapies for neurological disorders. The company generates revenue by discovering and developing drug candidates through its integrated platform that combines neuroscience, medicinal chemistry, and genetics, targeting specific neurological issues.
What is the highest forecasted price for RAPP Rapport Therapeutics Inc.?
The highest price target for RAPP is $42.00 from Justin Walsh at Jones Trading, which represents a 280.8% increase from the current price of $11.03.
What is the lowest forecasted price for RAPP Rapport Therapeutics Inc.?
The lowest price target for RAPP is $28.00 from Jason Butler at JMP Securities, which represents a 153.9% increase from the current price of $11.03.
What is the overall RAPP consensus from analysts for Rapport Therapeutics Inc.?
The overall analyst consensus for RAPP is bullish. Out of 5 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are RAPP stock price projections?
Stock price projections, including those for Rapport Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 10:51 AM UTC